Pre-Filled Syringes West Coast 2021

SMi Group 14 - 15 June 2021, San Diego, USA.
Following the success of the last event, the Pre-Filled Syringes West Coast conference is back to uncover the latest innovations in combination product development, device design, human factors engineering and drug product formulation to give a holistic overview of the industry and what we can expect for the future.

With the global market for prefilled syringes estimated to exceed $9.7bn by 2025, this year's agenda will encompass key drivers and hot topics of the industry including; updates to regulatory guidance from industry experts and regulatory bodies, case studies on device design and complex formulation, life cycle and control strategies, and innovations in connectivity and digital health.

This two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior PFS Engineers, Device Testing Managers, Heads of Late-Stage PFS Development and many more. PLUS, two interactive post conference workshops:

Workshop A: Connected devices and digital health: How to navigate the US FDA usability engineering requirements

Hosted by Shannon Clark, Principal, UserWise, Inc.

Workshop B: Postmarket safety reporting: The current regulatory environment with a global impact

Hosted by Khaudeja Bano, Sr. Medical Director, Abbott Molecular

Featured speakers

  • Brittney Pachucki, Device Engineer, AstraZeneca
  • Darin Zehrung, Global Program Leader, Medical Devices and Health Technologies, PATH
  • Jace Blackburn, Smart Device Engineer, Genentech
  • James P. Wabby, Executive Director, Regulatory Affairs - Device/Combination Products, Allergan
  • Jian Liu, Senior Scientist, Amgen
  • Khaudeja Bano, Senior, Medical Director, Abbott Diagnostics
  • Larry Atupem,  Sr Business Development Specialist, Zeon 
  • Maggie Reiff, Manager, Device Engineering, Pfizer
  • Mark DeStefano, Assoc. Dir. CPD Feasibility, New Technology and Prototyping Development, Teva Pharmaceuticals
  • Natalie Abts, Head of Human Factors Engineering, Genentech
  • Robert Ovadia, Engineer II, Genentech
  • Sarah Mollo, Combination Product Policy Analyst, FDA
  • Severine Duband, Global Category Manager, Nemera
  • Shannon Clark, Principal, UserWise, Inc.
  • Takuya Minezaki, Research Manager, Mitsubishi Gas Chemical Company, Inc.
  • Tina Rees, Associate Director - Human Factors, Ferring Pharmaceuticals
  • Tracy Hsu, Associate Director, Ionis Pharmaceuticals

Key reasons to attend

  • Engage in case study presentations from leading pharma and biotech companies on complex product formulation and optimising device design to aid delivery
  • Discuss show to optimise current processes to align with global regulatory updates
  • Delve into human factors engineering best practices
  • Uncover how industry is incorporating connectivity and digital health to optimise the user experience

Who should attend

Drug-delivery developers, Medical Device Engineers, Primary Packaging material designers, Secondary packagers, Smart device developers, Training device developers, Device-safety solution providers, Drug developers.

Early bird deadlines

  • Register by 31st March to save $200
  • Register by 30th April to save $100

For further information and to register, please visit:
http://www.prefilled-syringes-westcoast.com/wpnwl

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...